RT Journal Article
SR Electronic
A1 Hitt Nichols, Emma
T1 Reduced-Dose Conditioning Comparable to Standard Dose Prior to ASCT in MDS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 20
OP 21
DO 10.1177/1559897715570601
UL http://mdc.sagepub.com/content/14/55/20.abstract
AB New data from the RICMAC trial showed similar rates of non-relapse mortality, incidence of relapse, and relapse-free survival in patients with myelodysplastic syndrome or secondary acute myeloid leukemia after conditioning with reduced-dose busulfan plus fludarabine vs standard-dose busulfan plus cyclophosphamide prior to allogeneic stem cell transplantation. Overall survival was higher with the reduced dose, but results were not statistically significant.